Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
LV mass and paracardiac adipose tissue reductions may help lower the incidence of the kinds of adverse heart failure events that were seen in the main SUMMIT trial
TRT is for men (and women!) dealing with low testosterone, not
FDA Clears First Oral GLP-1 for Weight Loss On December 22, 2025, the FDA approved Novo Nordisks once-daily Wegovy pill (25 mg semaglutide), the first oral GLP-1 receptor agonist indicated for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight plus at least one weight-related comorbidity
Sterile water for injection
Increasingly used to support weight loss (with several countries authorizing the prescription of Novo Nordisks Wegovy and Eli Lillys Zepbound/Mounjaro drugs for weight management), the companies behind these drugs are reporting rapid sales growth and have seen their share prices rise significantly
Based on a recent third-party analysis conducted by the actuarial firm Accorded, Noom Med is expected to drive 4.1x ROI versus the most common alternative for employers who wish to cover GLP-1s for their workforce
